{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:45:22Z","timestamp":1761061522634},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In clinical practice, the risk factors for pegylated liposomal doxorubicin-related hand-foot syndrome remain unclear. The purpose of this study was to determine the risk factors associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective descriptive analysis included patients with lymphoma who received PLD treatment (\u2265 2\u2009cycles of chemotherapy) at our cancer centre and had complete follow-up data from January 2016 to February 2020. Clinical, laboratory data, as well as the occurrence of hand-foot syndrome (incidence, location, severity, impact on follow-up chemotherapy) were obtained. The primary end point was the incidence of hand-foot syndrome, which was classified according to the \u201cCommon Terminology Criteria for Adverse Events\u201d (Version 4.0). A multivariate logistic regression analysis was used to identify risk factors for hand-foot syndrome in patients with lymphoma using doxorubicin liposomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>A total of 167 patients met the inclusion criteria. 58 developed HFS, of which 45 occurred after the second course of chemotherapy. The multivariate logistic regression analysis revealed that a dose increase of pegylated liposomal doxorubicin and hepatobiliary dysfunction were significantly associated with an increased risk for hand-foot syndrome(dose intensity, OR\u2009=\u20096.479; 95% CI, 1.431\u201329.331 [<jats:italic>P<\/jats:italic>\u2009=\u20090.015]; history of gallstones, OR\u2009=\u200914.144, 95% CI, 1.512\u2013132.346 [<jats:italic>P<\/jats:italic>\u2009=\u20090.020]; alanine aminotransferase, OR\u2009=\u20091.194, 95% CI, 1.056\u20131.350 [<jats:italic>P<\/jats:italic>\u2009=\u20090.005]; aspartate aminotransferase, OR\u2009=\u20091.162, 95% CI, 1.010\u20131.336 [<jats:italic>P<\/jats:italic>\u2009=\u20090.035]; and glutamine transpeptidase, OR\u2009=\u20091.092, 95% CI, 1.016\u20131.174 [<jats:italic>P<\/jats:italic>\u2009=\u20090.018]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Implications<\/jats:title>\n                <jats:p>These findings contribute to the risk assessment of patients with lymphoma before using pegylated liposomal doxorubicin. For patients with the above risk factors, preventive measures should be taken in advance to reduce the incidence of HFS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-021-00529-3","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T05:03:08Z","timestamp":1635138188000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanfang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liru","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingjian","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"3","key":"529_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305(3):139\u201353. https:\/\/doi.org\/10.1056\/NEJM198107163050305.","journal-title":"N Engl J Med"},{"key":"529_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff DD, Layard M, Basa W, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710\u20137. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710.","journal-title":"Ann Intern Med"},{"issue":"1","key":"529_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1006\/gyno.1994.1102","volume":"8","author":"AA Gabizon","year":"1994","unstructured":"Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8(1):431\u201350. https:\/\/doi.org\/10.1006\/gyno.1994.1102.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"529_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylatedliposomal doxorubicin. Clin Pharmacokinet. 2003;42(5):419\u201336. https:\/\/doi.org\/10.2165\/00003088-200342050-00002.","journal-title":"Clin Pharmacokinet"},{"key":"529_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat. 2016;29:90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"529_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medi-cal tumor therapy\u2014classification and management. J DtschDermatol Ges. 2010;8(9):652\u201361. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x.","journal-title":"J DtschDermatol Ges"},{"issue":"3","key":"529_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","volume":"11","author":"JD Webster-Gandy","year":"2007","unstructured":"Webster-Gandy JD, How C, Harrold K. Palmar\u2013plantar erythrodysesthesia (PPE): a literature review with commentary onexperience in a cancer Centre. Eur J Oncol Nurs. 2007;11(3):238\u201346. https:\/\/doi.org\/10.1016\/j.ejon.2006.10.004.","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"529_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","volume":"16","author":"M Hackbarth","year":"2008","unstructured":"Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J. Chemotherapy-induced dermatological toxicity: frequenciesand impact on quality of life in women\u2019s cancers. Results of aprospective study. Support Care Cancer. 2008;16(3):267\u201373. https:\/\/doi.org\/10.1007\/s00520-007-0318-8.","journal-title":"Support Care Cancer"},{"issue":"4","key":"529_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"529_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdh097.","journal-title":"Ann Oncol"},{"issue":"4","key":"529_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","volume":"1","author":"E Nagore","year":"2000","unstructured":"Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-inducedpalmar plantar erhthrodysesthesia (\u2018hand-foot\u2019) syndrome: inci-dence, recognision and management. Am J Clin Dermatol. 2000;1(4):225\u201334. https:\/\/doi.org\/10.2165\/00128071-200001040-00004.","journal-title":"Am J Clin Dermatol"},{"key":"529_CR12","volume-title":"Common terminology criteria for adverse events v4.0 (CTCAE)","author":"National Cancer Institute","year":"2009","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v4.0 (CTCAE). 2009. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"7","key":"529_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18(7):1159\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdl477.","journal-title":"Ann Oncol"},{"issue":"3","key":"529_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-b","volume":"24","author":"BR Baack","year":"1991","unstructured":"Baack BR. Burgdorf WHC chemotherapy-induced acral erythema. JAm Acad Dermatol. 1991;24(3):457\u201361. https:\/\/doi.org\/10.1016\/0190-9622(91)70073-b.","journal-title":"JAm Acad Dermatol"},{"issue":"1","key":"529_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-reilly A, et al. Pathogenesis of hand-foot syndrome induced by PEG modified liposomal doxorubin. Hum Cell. 2013;26(1):8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0.","journal-title":"Hum Cell"},{"issue":"12","key":"529_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","volume":"136","author":"M Lotem","year":"2000","unstructured":"Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136(12):1475\u201380. https:\/\/doi.org\/10.1001\/archderm.136.12.1475.","journal-title":"Arch Dermatol"},{"issue":"3","key":"529_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1034\/j.1600-0560.2002.290304.x","volume":"29","author":"H Skelton","year":"2002","unstructured":"Skelton H, Linstrum J, Smith K. Host vs.-altered-host eruptions in patients on liposomal doxorubicin. J Cutan Pathol. 2002;29(3):148\u201353. https:\/\/doi.org\/10.1034\/j.1600-0560.2002.290304.x.","journal-title":"J Cutan Pathol"},{"issue":"16_suppl","key":"529_CR18","doi-asserted-by":"publisher","first-page":"8198","DOI":"10.1200\/jco.2005.23.16_suppl.8198","volume":"23","author":"N Grenier","year":"2005","unstructured":"Grenier N, Lebel V, Gill M, Mitchinson K, Foster M, Lewis S, et al. Nursing support program to decreaseor prevent side effects of pegylated liposomal doxorubicin (PLD) inpatients with recurrent epithelial ovarian cancer (REOC). Proc AmSoc Clin Oncol. 2005;23(16_suppl):8198. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.8198.","journal-title":"Proc AmSoc Clin Oncol"},{"issue":"5","key":"529_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics ofpegylated liposomal doxorubicin: review of animal and humanstudies. Clin Pharmacokinet. 2003;42(5):419\u201336. https:\/\/doi.org\/10.2165\/00003088-200342050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"529_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/096032719601500906","volume":"15","author":"PK Working","year":"1996","unstructured":"Working PK, Dayan AD. Pharmacological-toxicological expert report. Caelyx\u2122. (stealth\u00ae liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15(9):752\u201385. https:\/\/doi.org\/10.1177\/096032719601500906.","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"529_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94(2):320\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.027.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"529_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","volume":"10","author":"RF Schell","year":"2014","unstructured":"Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, et al. Meta-analysis of inter-patientpharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine. 2014;10(1):109\u201317. https:\/\/doi.org\/10.1016\/j.nano.2013.07.005.","journal-title":"Nanomedicine."},{"issue":"1","key":"529_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","volume":"69","author":"NM La-Beck","year":"2012","unstructured":"La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, et al. Factors affecting the pharmacokinetics of pegylatedliposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2012;69(1):43\u201350. https:\/\/doi.org\/10.1007\/s00280-011-1664-2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"529_CR24","doi-asserted-by":"publisher","unstructured":"Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zhou H, Monaco JH, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump V.L,Gehrig PA, Zamboni WC. Translational studies of phenotypic probesfor the mononuclear phagocyte system and liposomal pharmacology. J Pharmacol Exp Ther 2013;347:599\u2013606. doi: https:\/\/doi.org\/10.1124\/jpet.113.208801, 3.","DOI":"10.1124\/jpet.113.208801"},{"issue":"4","key":"529_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","volume":"61","author":"A Gabizon","year":"2008","unstructured":"Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycledependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2008;61(4):695\u2013702. https:\/\/doi.org\/10.1007\/s00280-007-0525-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"529_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00001813-200002000-00009","volume":"11","author":"A Hubert","year":"2000","unstructured":"Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): anexploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anti-Cancer Drugs. 2000;11(2):123\u20137. https:\/\/doi.org\/10.1097\/00001813-200002000-00009.","journal-title":"Anti-Cancer Drugs"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-021-00529-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T05:10:02Z","timestamp":1635138602000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-021-00529-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/s40360-021-00529-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of The Harbin Medical University Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}